Medtronic stock firms ahead of September earnings as analysts lift expectations

Medtronic plc (ISIN IE00BTN1Y115) stock is trading in the low-$90 range as of August 28, 2026, with investors positioning ahead of the company’s next earnings release and several analysts signaling higher expectations for the coming fiscal year.

Shares hold near $92 into earnings

Per a recent market-data overview, Medtronic’s New York Stock Exchange-listed shares last closed at $92.09 on August 28, 2026, up $1.49 on the day, a gain of 1.64 percent that keeps the stock close to the $92 mark ahead of the next catalyst. The same overview shows an after-hours indication at $90.00, 2.27 percent below the regular-session close, underscoring that traders are already adjusting positions in advance of fresh numbers.

At this price zone, Medtronic remains well above levels earlier in the year when the shares traded in the high-$80s, and the latest move has helped rebuild momentum going into a dense period of healthcare earnings. For many investors, that combination of a firm share price near $92 and a clear upcoming date concentrates attention on how Medtronic’s fundamentals will evolve across fiscal 2027.

Upcoming earnings and consensus expectations

According to an earnings calendar compiled by a financial news service, Medtronic is scheduled to report its next results on September 1, 2026, before the opening of US markets. This timing means the numbers will be out just days after the most recent trading session referenced above, giving investors little time between the current price snapshot and the new data.

Recent coverage of analyst expectations indicates that the first quarter of the new fiscal year is forecast to show adjusted earnings per share of $1.39 and revenue of $9.54 billion. Those figures sit at the heart of the current consensus and frame how the market will judge Medtronic’s performance: if the company delivers EPS above $1.39 or revenue above $9.54 billion, the result would be an upside surprise against what analysts presently model, while misses versus these thresholds would likely test the stock’s resilience near $92.

The same overview notes that some analyst commentary now anticipates Medtronic not only meeting but potentially exceeding the first-quarter consensus and using the report to raise full fiscal 2027 guidance. That would reinforce a narrative of accelerating growth after prior years in which revenue and earnings expanded more slowly, and it could support a rerating of the shares if the guidance lift is material.

Analyst targets shift higher

One piece of recent analysis highlights that at least one research firm has moved its price target into triple-digit territory, lifting the target to $114 from a prior level of $101 while maintaining a positive recommendation on Medtronic. That change represents a 12.87 percent increase in the target level and implies notable upside versus the stock’s latest close at $92.09.

Against that backdrop, the implied upside from $92.09 to $114 is $21.91 per share, or 23.78 percent, which is a meaningful gap for a large, established healthcare technology company. The analyst commentary associated with the new target explicitly points to a belief that Medtronic can beat the first-quarter consensus outlined above and can raise its fiscal 2027 guidance, suggesting that any confirmation of those themes in the September 1 release could be a catalyst for further gains.

For investors, the quantified comparison between the current share price near $92 and the raised target at $114 helps frame risk and reward. If the earnings report confirms accelerating growth and stronger guidance, the gap between price and target may narrow, while a weaker-than-expected update could prompt a reassessment of such optimistic assumptions and pull the shares back from their current zone.

A diversified portfolio of medical technologies

Beyond near-term market moves, Medtronic’s core business remains centered on a broad portfolio of medical devices and technologies spanning cardiovascular, diabetes, neuroscience, and surgical segments. A representative product in this portfolio is its line of cardiac rhythm management devices, including implantable pacemakers designed to help patients maintain stable heart rhythms and reduce the risk of serious complications.

Devices in this category are typically supported by long-term clinical data and are embedded in treatment standards for arrhythmias, making them a recurring revenue driver through new implants, replacements, and associated services. For investors evaluating Medtronic as a long-term holding, the continued innovation and regulatory maintenance in such core device families often matter as much as short-term earnings surprises, because they underpin the company’s ability to defend market share and sustain cash flows.

Stock level heading into the next report

As of the close on August 28, 2026, Medtronic stock trades at $92.09 on the New York Stock Exchange in US dollars, with an after-hours indication at $90.00 providing a slightly lower reference point ahead of the September 1 earnings release. That price level, combined with consensus forecasts of $1.39 in adjusted EPS and $9.54 billion in revenue for the upcoming quarter and at least one price target lifted to $114, sets the stage for an important test of expectations that could influence the stock’s path through the remainder of fiscal 2027.

Fact box

Company: Medtronic plc
ISIN: IE00BTN1Y115
Ticker: MDT
Exchange: New York Stock Exchange
Price (as of August 28, 2026, 4:00 p.m. ET): $92.09 USD
Sector / Industry: Healthcare equipment and supplies
Index membership: S&P 500
Next earnings date: September 1, 2026